MYD88 and gout: It targets the Toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MyD88)/NF-κB pathway, thereby inhibiting the inflammatory process.11 Nevertheless, the molecular mechanism by which miR-23a-5p regulates immune control in gout remains unclear.